CAAS
BPMC

Capital Asset Advisory Services’s Blueprint Medicines BPMC Stock Holding History

Capital Asset Advisory Services’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-168
Closed -$19K – 762
2020
Q4 		$19K Buy
+168
New +$17.7K ﹤0.01% 889

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital Asset Advisory Services's BPMC Position: Q1 2021 in Review

Capital Asset Advisory Services sold out of Blueprint Medicines (BPMC) in Q1 2021, closing a stake of 168 shares — an estimated $19K sold.

Capital Asset Advisory Services first reported a position in BPMC in Q4 2020 and held it in 1 quarter. The position peaked at $19K in Q4 2020. 263 funds tracked by Wall St. Rank hold BPMC as of Q1 2021.

  • Capital Asset Advisory Services reported no remaining Blueprint Medicines position as of Q1 2021 after selling out during the quarter.
  • Capital Asset Advisory Services sold 168 Blueprint Medicines shares in Q1 2021, an estimated $19K.
  • Capital Asset Advisory Services first reported a position in Blueprint Medicines in Q4 2020 and held it in 1 quarter.
  • Capital Asset Advisory Services's Blueprint Medicines position peaked at $19K in Q4 2020.
  • 263 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2021.

Based on Capital Asset Advisory Services's 13F filing for Q1 2021, filed 13 May 2021.